The clinicopathological characteristics, oncologic outcomes and costs of "HER2-low" early breast cancer compared to HER2-zero and HER2-positive: a single-centre retrospective analysis [0.03%]
与HER2阴性和HER2阳性乳腺癌相比，“低HER2”乳腺癌的临床病理特征、肿瘤结局和成本：一项单中心回顾性分析
Patrícia Rafaela Rodrigues,Luísa Lopes-Conceição,Virgínia Sousa et al.
Patrícia Rafaela Rodrigues et al.
Background: Breast cancer is a heterogeneous disease commonly classified based on hormone receptor (HR) status and human epidermal growth factor receptor 2 (HER2) expression. Recently, an intermediate category termed "HER...
3D-printed biopolymer-based microneedle for enhanced photodynamic therapy in melanoma treatment [0.03%]
基于生物聚合物的微针3D打印技术在增强黑色素瘤光动力治疗中的应用研究
Aishat Adejoke Obalola,Heidi Abrahamse,Sathish Sundar Dhilip Kumar
Aishat Adejoke Obalola
Melanoma is a highly aggressive cancer with poor prognosis and resistance to many treatments, especially after metastasis. Developing new preventive and adjuvant therapies is critical for improving melanoma outcomes. Photodynamic therapy (P...
Integration of autophagy-related genes and immune dysregulation reveals a prognostic landscape in multiple myeloma [0.03%]
自噬相关基因与免疫失调的整合揭示了多发性骨髓瘤中的预后特征地图
Yibo Xia,Dong Zheng,Xinyi Zhang et al.
Yibo Xia et al.
Background: Autophagy is a self-renewal mechanism in which cells degrade damaged organelles or abnormal proteins through lysosomes. This process eliminates harmful components within the cell and maintains energy homeostas...
Anti-lipolysis-stimulated lipoprotein receptor antibody-drug conjugate to treat triple-negative breast cancer [0.03%]
抗脂解刺激性载脂蛋白受体的抗体药物偶联物治疗三阴性乳腺癌
Zhuoxin Zora Zhou,Davis Ballard,Tanvi Varadkar et al.
Zhuoxin Zora Zhou et al.
Triple-negative breast cancer (TNBC), the most aggressive breast cancer subtype (ER-/PR-/HER2-), is characterized by rapid proliferation, high metastatic rate and frequent recurrence. The development of targeted therapies for TNBC, such as ...
Tingyu Feng,Tianyang He,Wentao Ye et al.
Tingyu Feng et al.
FLASH radiotherapy (FLASH-RT) represents an innovative treatment modality utilizing ultra-high dose-rate irradiation (>40 Gy/s). The FLASH effect, induced by FLASH-RT, is characterized by the selective radioprotective effect of normal tissu...
Efficacy and safety of the S-1, nab-paclitaxel, and gemcitabine triplet regimen in patients with resected pancreatic ductal adenocarcinoma [0.03%]
S-1，白蛋白结合型紫杉醇和吉西他滨三联方案治疗胰腺导管腺癌术后患者的有效性和安全性评估研究
Donghui Ran,Cheng Geng,Zhongming Cha et al.
Donghui Ran et al.
Objective: To evaluate the safety, feasibility, and efficacy of an S-1-based triplet regimen (with nab-paclitaxel and gemcitabine) as adjuvant therapy following curative resection for pancreatic ductal adenocarcinoma (PDA...
Exploring 2D and 3D radiomic models for predicting microvascular invasion in hepatocellular carcinoma: a novel perspective on tumor heterogeneity [0.03%]
从肿瘤异质性的新视角探索肝细胞癌微血管侵犯的二维和三维影像组学模型
Zexin Yin,Meilong Wu,Youyao Li et al.
Zexin Yin et al.
Objective: This study aims to develop models for predicting microvascular invasion (MVI) in hepatocellular carcinoma (HCC) patients prior to surgery using two-dimensional (2D) and three-dimensional (3D) radiomics features...
A discrete choice experiment analysis to understand patient preferences for multiple myeloma treatments [0.03%]
应用离散选择试验分析了解患者对于治疗多发性骨髓瘤的偏好
Beth Faiman,Hoa H Le,Julie Laurent et al.
Beth Faiman et al.
Introduction: Multiple myeloma (MM) is a malignant plasma cell disorder characterized by the clonal expansion of abnormal plasma cells within the bone marrow. The management of relapsed/refractory multiple myeloma (RRMM) ...
Identification of amino acid metabolism-related gene Leucyl-tRNA synthetase 1 (LARS1) as a potential prognostic and therapeutic target in hepatocellular carcinoma [0.03%]
肝癌中与氨基酸代谢相关的基因亮氨酰-tRNA合成酶1（LARS1）的鉴定及其作为潜在预后和治疗靶点的作用
Qiyu Shi,Yirong Chi,Ziyi Peng et al.
Qiyu Shi et al.
Introduction: Amino acid metabolism plays a critical role in tumorigenesis in hepatocellular carcinoma (HCC). Thus, we explore the amino acid metabolic profile in HCC to construct effective prognosis model and identify no...
Efficacy and survival analysis of neoadjuvant chemotherapy combined with immunotherapy in locally advanced resectable Siewert type II adenocarcinoma of the esophagogastric junction [0.03%]
新辅助化疗联合免疫治疗在可切除的Siewert Ⅱ型食管胃交界部腺癌中的疗效及生存分析
Chunyue Gai,Huilai Lv,Cuili Feng et al.
Chunyue Gai et al.
Background: Neoadjuvant chemotherapy combined with immunotherapy (nCI) has achieved significant results in esophageal and gastric cancers, but its efficacy in Siewert type II adenocarcinoma of the esophagogastric junction...